Washer Susan B.'s Form 4 filing
Applied Genetic Technologies Corp (AGTC) · filed Feb 22, 2022
- Accession no.
- 0001062993-22-005202
- Filed
- Feb 22, 2022, 9:34 PM ET
- Trade date
- Feb 18, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $21.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Washer Susan B.CIK 0001598540 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2022 | Common Stock | MOption exerciseAcquired | +120,686 | $0.35 | +$42,240.1 | 152,971 | Direct | |
| Feb 18, 2022 | Common Stock | SSaleDisposed | −9,950 | $2.18F1 | −$21,691 | 143,021 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2022 | Common Stock | MOption exerciseDisposed | −120,686 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.22, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
The reporting person undertakes to provide to Applied Genetic Technologies Corporation, any security holder of Applied Genetic Technologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above.